{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T00:26:13Z","timestamp":1792887973912,"version":"4.5.0"},"reference-count":48,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T00:00:00Z","timestamp":1708560000000},"content-version":"unspecified","delay-in-days":21,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018731","name":"Jiangsu Hengrui Pharmaceuticals Co., Ltd","doi-asserted-by":"crossref","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100018731","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2024,1,29]]},"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The combination of immune-checkpoint inhibitors and antiangiogenic agents can synergistically modulate the tumor microenvironment and represents a promising treatment option. Here, we evaluated the efficacy and safety of camrelizumab plus famitinib (a receptor tyrosine kinase inhibitor) as a first-line treatment for advanced or metastatic NSCLC patients with a programmed death ligand-1 (PD-L1) tumor proportion score (TPS) of \u22651%, in an open-label, multicenter, phase 2 basket trial.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Eligible patients received camrelizumab (200\u2009mg once every 3 weeks via intravenous infusion) plus oral famitinib at an initial dose of 20\u2009mg once daily. The primary endpoint was the objective response rate (ORR), as assessed by the investigator per Response Evaluation Criteria in Solid Tumors V.1.1. Key secondary endpoints included disease control rate (DCR), duration of respons, progression-free survival (PFS), overall survival (OS), 12-month OS rate, and safety profile.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of the enrolled 41 patients, 21 (51.2%) had a PD-L1 TPS of 1\u201349%. As of the cut-off date on June 22, 2022, the combination regimen of camrelizumab and famitinib achieved an ORR of 53.7% (95% CI 37.4% to 69.3%) and a DCR of 92.7% (95% CI 80.1% to 98.5%). The median PFS was 16.6 months (95%\u2009CI 8.3 to not reached), and OS data were not yet mature, with an estimated 12-month OS rate of 76.8% (95% CI 60.0% to 87.3%). The most common treatment-related adverse events of grade 3 or higher included hypertension (22.0%), increased alanine aminotransferase (12.2%), decreased neutrophil count (9.8%), proteinuria (7.3%), decrease platelet count (7.3%), and hypokalemia (7.3%). One (2.4%) patient died from grade 5 hemoptysis, which was considered possibly related to the study treatment by the investigator.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Camrelizumab plus famitinib demonstrated promising antitumor activity in advanced or metastatic NSCLC patients and had an acceptable safety profile. These findings suggest that this combination regimen could be an alternative therapeutic option and warrant further investigation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>\n                     <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" specific-use=\"clinicaltrial results\" xlink:href=\"NCT04346381\">NCT04346381<\/jats:ext-link>.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2023-007227","type":"journal-article","created":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T01:53:35Z","timestamp":1708566815000},"page":"e007227","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":11,"title":["First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS \u22651%: results from a multicenter, open-label, phase 2 trial"],"prefix":"10.1136","volume":"12","clinical-trial-number":[{"clinical-trial-number":"nct04346381","registry":"10.18810\/clinical-trials-gov","type":"results"},{"clinical-trial-number":"nct05042375","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04346381","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05042375","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05042375","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Shengxiang","family":"Ren","sequence":"first","affiliation":[{"name":"Oncology Department, Shanghai Pulmonary Hospital, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xicheng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology, the First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3534-093X","authenticated-orcid":false,"given":"Bao-Hui","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Respiration, Shanghai Chest Hospital, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueyin","family":"Pan","sequence":"additional","affiliation":[{"name":"Oncology Chemotherapy Department, The First Affiliated Hospital of USTC (Anhui Provincial Hospital), Hefei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Thoracic Medical Oncology, Beijing Cancer Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufeng","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Chemotherapy, Qilu Hospital of Shandong University, Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2709-6976","authenticated-orcid":false,"given":"Sheng","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Thoracic Tumor, Hubei Cancer Hospital, Wuhan, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianshu","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yalun","family":"Li","sequence":"additional","affiliation":[{"name":"Respiratory and Critical Care Medicine, West China School of Medicine\/West China Hospital of Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9908-597X","authenticated-orcid":false,"given":"Ying","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Jilin Cancer Hospital, Changchun, Jilin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jifeng","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, the Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanyong","family":"Yi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Zhengzhou Central Hospital, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanzhi","family":"Gu","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology, Hunan Cancer Hospital, Changsha, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shegan","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongzhong","family":"Luo","sequence":"additional","affiliation":[{"name":"Thoracic Medicine Department, Hunan Cancer Hospital & the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caigang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijie","family":"Duan","sequence":"additional","affiliation":[{"name":"Clinical Research & Development, Jiangsu Hengrui Pharmaceuticals Co Ltd, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuni","family":"Wang","sequence":"additional","affiliation":[{"name":"Clinical Research & Development, Jiangsu Hengrui Pharmaceuticals Co Ltd, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinfeng","family":"Yang","sequence":"additional","affiliation":[{"name":"Clinical Research & Development, Jiangsu Hengrui Pharmaceuticals Co Ltd, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1072-9941","authenticated-orcid":false,"given":"Caicun","family":"Zhou","sequence":"additional","affiliation":[{"name":"Oncology Department, Shanghai Pulmonary Hospital, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,2,21]]},"reference":[{"key":"2025100312464431000_12.2.e007227.1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0025"},{"key":"2025100312464431000_12.2.e007227.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32409-7"},{"key":"2025100312464431000_12.2.e007227.3","doi-asserted-by":"publisher","DOI":"10.1200\/Jco.21.01497"},{"key":"2025100312464431000_12.2.e007227.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716948"},{"key":"2025100312464431000_12.2.e007227.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1810865"},{"key":"2025100312464431000_12.2.e007227.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801005"},{"key":"2025100312464431000_12.2.e007227.7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30167-6"},{"key":"2025100312464431000_12.2.e007227.8","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1002\/hep.30889","article-title":"Dual programmed death receptor\u20101 and vascular endothelial growth factor receptor\u20102 blockade promotes vascular normalization and enhances antitumor immune responses in hepatocellular carcinoma","volume":"71","author":"Shigeta","year":"2020","journal-title":"Hepatology"},{"key":"2025100312464431000_12.2.e007227.9","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-0153"},{"key":"2025100312464431000_12.2.e007227.10","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0640"},{"issue":"15_suppl","key":"2025100312464431000_12.2.e007227.11","doi-asserted-by":"crossref","first-page":"4074","DOI":"10.1200\/JCO.2018.36.15_suppl.4074","article-title":"Safety and clinical activity of 1L atezolizumab + bevacizumab in a phase Ib study in hepatocellular carcinoma (HCC)","volume":"36","author":"Stein","year":"2018","journal-title":"JCO"},{"key":"2025100312464431000_12.2.e007227.12","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/cas.14294","article-title":"Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101","volume":"111","author":"Uemura","year":"2020","journal-title":"Cancer Sci"},{"key":"2025100312464431000_12.2.e007227.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1816714"},{"key":"2025100312464431000_12.2.e007227.14","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30020-8"},{"key":"2025100312464431000_12.2.e007227.15","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.jtho.2020.11.026","article-title":"Phase 1b study of sintilimab plus anlotinib as first-line therapy in patients with advanced NSCLC","volume":"16","author":"Chu","year":"2021","journal-title":"J Thorac Oncol"},{"key":"2025100312464431000_12.2.e007227.16","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30458-9"},{"issue":"8_suppl","key":"2025100312464431000_12.2.e007227.17","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1200\/JCO.2019.37.8_suppl.16","article-title":"A phase Ib\/II trial of lenvatinib plus pembrolizumab in non-small cell lung cancer","volume":"37","author":"Brose","year":"2019","journal-title":"JCO"},{"key":"2025100312464431000_12.2.e007227.18","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s40265-019-01167-0","article-title":"Camrelizumab: first global approval","volume":"79","author":"Markham","year":"2019","journal-title":"Drugs"},{"key":"2025100312464431000_12.2.e007227.19","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S2213-2600(20)30365-9","article-title":"Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial","volume":"9","author":"Zhou","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2025100312464431000_12.2.e007227.20","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.jtho.2021.11.018","article-title":"Camrelizumab plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC (CameL-Sq): a phase 3 trial","volume":"17","author":"Ren","year":"2022","journal-title":"J Thorac Oncol"},{"key":"2025100312464431000_12.2.e007227.21","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s00280-013-2282-y","article-title":"Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib","volume":"72","author":"Zhou","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"2025100312464431000_12.2.e007227.22","doi-asserted-by":"publisher","DOI":"10.1111\/bph.12047"},{"key":"2025100312464431000_12.2.e007227.23","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003831","article-title":"Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket study","volume":"10","author":"Xia","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2025100312464431000_12.2.e007227.24","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1698"},{"key":"2025100312464431000_12.2.e007227.25","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004427","article-title":"Camrelizumab plus famitinib for advanced or metastatic urothelial carcinoma after platinum-based therapy: data from a multicohort phase 2 study","volume":"10","author":"Qu","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2025100312464431000_12.2.e007227.26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801946"},{"key":"2025100312464431000_12.2.e007227.27","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1200\/JCO.18.01042","article-title":"First-line nivolumab plus ipilimumab in advanced non-small-cell lung cancer (checkMate 568): outcomes by programmed death ligand 1 and tumor mutational burden as biomarkers","volume":"37","author":"Ready","year":"2019","journal-title":"J Clin Oncol"},{"key":"2025100312464431000_12.2.e007227.28","doi-asserted-by":"crossref","first-page":"S225","DOI":"10.1016\/j.jtho.2021.01.143","article-title":"FP13.04 KEYNOTE-042 3-year survival update: 1L pembrolizumab vs platinum-based chemotherapy for PD-L1+ locally advanced\/metastatic NSCLC","volume":"16","author":"Cho","year":"2021","journal-title":"Journal of Thoracic Oncology"},{"key":"2025100312464431000_12.2.e007227.29","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1002\/ijc.33399","article-title":"Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD-L1-positive locally advanced or metastatic non-small-cell lung cancer: KEYNOTE-042 China Study","volume":"148","author":"Wu","year":"2021","journal-title":"Int J Cancer"},{"key":"2025100312464431000_12.2.e007227.30","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jtho.2020.10.004","article-title":"Phase 1 expansion cohort of ramucirumab plus pembrolizumab in advanced treatment-naive NSCLC","volume":"16","author":"Herbst","year":"2021","journal-title":"J Thorac Oncol"},{"key":"2025100312464431000_12.2.e007227.31","doi-asserted-by":"crossref","unstructured":"Yang J-H , Han B , De La Mora Jim\u00e9nez E , et al . Pembrolizumab with or without lenvatinib for first-line metastatic non\u2012small-cell lung cancer with PD-L1 tumor proportion score \u22651% (LEAP-007): a randomized, double-blind, phase 3 trial. J Thorac Oncol 2023. doi:10.1016\/j.jtho.2023.12.023","DOI":"10.1016\/j.jtho.2023.12.023"},{"key":"2025100312464431000_12.2.e007227.32","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/S1556-0864(23)00260-5","article-title":"60 CONTACT-01: Efficacy and safety from a phase III study of atezolizumab (atezo) + cabozantinib (cabo) vs docetaxel (doc) monotherapy in patients (pts) with metastatic NSCLC (mNSCLC) previously treated with checkpoint inhibitors and chemotherapy","volume":"18","author":"Neal","year":"2023","journal-title":"J Thora Oncol"},{"key":"2025100312464431000_12.2.e007227.33","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-08887-7","article-title":"The Aryl hydrocarbon receptor mediates tobacco-induced PD-L1 expression and is associated with response to immunotherapy","volume":"10","author":"Wang","year":"2019","journal-title":"Nat Commun"},{"key":"2025100312464431000_12.2.e007227.34","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2018-000406","article-title":"Tobacco smoking and cessation and PD-L1 inhibitors in non-small cell lung cancer (NSCLC): a review of the literature","volume":"3","author":"Norum","year":"2018","journal-title":"ESMO Open"},{"key":"2025100312464431000_12.2.e007227.35","doi-asserted-by":"crossref","first-page":"745859","DOI":"10.3389\/fcell.2021.745859","article-title":"The effect of smoking on the immune microenvironment and immunogenicity and its relationship with the prognosis of immune checkpoint inhibitors in non-small cell lung cancer","volume":"9","author":"Sun","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"2025100312464431000_12.2.e007227.36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774"},{"key":"2025100312464431000_12.2.e007227.37","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1007\/s00262-021-03091-3","article-title":"Camrelizumab in different PD-L1 expression cohorts of pre-treated advanced or metastatic non-small cell lung cancer: a phase II study","volume":"71","author":"Yang","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"2025100312464431000_12.2.e007227.38","doi-asserted-by":"crossref","DOI":"10.1186\/s40880-017-0263-y","article-title":"Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial","volume":"36","author":"Xu","year":"2017","journal-title":"Chin J Cancer"},{"key":"2025100312464431000_12.2.e007227.39","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.3760\/cma.j.issn.0366-6999.20131757","article-title":"Famitinib in metastatic renal cell carcinoma: a single center study","volume":"126","author":"Zhang","year":"2013","journal-title":"Chin Med J"},{"key":"2025100312464431000_12.2.e007227.40","doi-asserted-by":"crossref","first-page":"173","DOI":"10.20892\/j.issn.2095-3941.2018.0172","article-title":"Reactive capillary hemangiomas: a novel dermatologic toxicity following anti-PD-1 treatment with SHR-1210","volume":"16","author":"Xuelian","year":"2019","journal-title":"Cancer Biology & Medicine"},{"key":"2025100312464431000_12.2.e007227.41","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3136"},{"key":"2025100312464431000_12.2.e007227.42","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2484"},{"key":"2025100312464431000_12.2.e007227.43","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4691"},{"key":"2025100312464431000_12.2.e007227.44","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30110-8"},{"key":"2025100312464431000_12.2.e007227.45","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/jitc-2021-003790","article-title":"Efficacy, safety, and biomarker analysis of camrelizumab in previously treated recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN study)","volume":"9","author":"Yang","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025100312464431000_12.2.e007227.46","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S1470-2045(20)30011-5","article-title":"Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial","volume":"21","author":"Qin","year":"2020","journal-title":"The Lancet Oncology"},{"key":"2025100312464431000_12.2.e007227.47","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1158\/1078-0432.CCR-21-4313","article-title":"Famitinib with camrelizumab and nab-paclitaxel for advanced immunomodulatory triple-negative breast cancer (FUTURE-C-Plus): an open-label, single-arm, phase II trial","volume":"28","author":"Chen","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2025100312464431000_12.2.e007227.48","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-35133-4","article-title":"A multicenter phase 2 trial of camrelizumab plus famitinib for women with recurrent or metastatic cervical squamous cell carcinoma","volume":"13","author":"Xia","year":"2022","journal-title":"Nat Commun"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2023-007227","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T19:46:57Z","timestamp":1759520817000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2023-007227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":48,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2,21]]},"published-print":{"date-parts":[[2024,2]]}},"alternative-id":["10.1136\/jitc-2023-007227"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2023-007227","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2]]}}}